AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes
13-Sep-2004 -
AVI BioPharma, Inc. (Nasdaq: AVII), today announced it presented data on its NeuGene® antisense approach to transplant acceptance at the 20th International Congress of the Transplantation Society, held in Vienna, Austria, Sept. 5-10, 2004.
The presentation, titled "Antisense Inhibition of cFLIP ...
apoptosis
bone marrow
immune cells
+2